Floatz logo

rc48-adc

Pancreatic Carcinoma

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical Schoolantibody_drug_conjugatePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Alliance for Clinical Trials in Oncology
Phase 2/3BB
Cyclophosphamide
Essen Biotech
Phase 2B
Veliparib
National Cancer Institute (NCI)
Phase 2B
Epirubicin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2B
Pembrolizumab
Xencor, Inc.
Phase 2B

View all 49 →

Same molecule, other indications

rc48-adc is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →